Keywords: prosidion, begins, ph, ii, antidiabetes, drug, osi

Prosidion begins Ph II of antidiabetes drug

Article | 24 January 2005

Print This

OSI Pharmaceuticals of the USA says that its UK-based subsidiary Prosidion has initiated a Phase II proof-of-concept and dose range-finding ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in